Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
48
CMPX Quote, Financials, Valuation and Earnings
Last price:
$5.44
Seasonality move
:
9.93%
Day range:
$5.18 - $5.50
52-week range:
$1.40 - $6.88
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.00x
Volume:
3.2M
Avg. volume:
2.2M
1-year change:
222.49%
Market cap:
$983.3M
Revenue:
--
EPS (TTM):
-$0.43
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CMPX
Compass Therapeutics, Inc.
|
-- | -$0.10 | -100% | -18.8% | $13.64 |
|
EKSO
Ekso Bionics Holdings, Inc.
|
$4.3M | -- | -1.27% | -- | $9.50 |
|
FOLD
Amicus Therapeutics, Inc.
|
$180.9M | $0.02 | 16.93% | 267.32% | $14.50 |
|
IBRX
ImmunityBio, Inc.
|
$48.2M | -$0.06 | 161.36% | -53.95% | $14.80 |
|
INSM
Insmed, Inc.
|
$385.6M | -$0.81 | 259.02% | -30.12% | $214.32 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CMPX
Compass Therapeutics, Inc.
|
$5.45 | $13.64 | $983.3M | -- | $0.00 | 0% | -- |
|
EKSO
Ekso Bionics Holdings, Inc.
|
$9.40 | $9.50 | $29.3M | -- | $0.00 | 0% | 5.32x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.44 | $14.50 | $4.5B | -- | $0.00 | 0% | 7.06x |
|
IBRX
ImmunityBio, Inc.
|
$7.30 | $14.80 | $7.7B | -- | $0.00 | 0% | 60.49x |
|
INSM
Insmed, Inc.
|
$162.43 | $214.32 | $34.5B | -- | $0.00 | 0% | 53.27x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CMPX
Compass Therapeutics, Inc.
|
4.76% | 2.020 | 1.03% | 14.96x |
|
EKSO
Ekso Bionics Holdings, Inc.
|
33.97% | -3.939 | 15.84% | 0.98x |
|
FOLD
Amicus Therapeutics, Inc.
|
61.73% | -1.478 | 9.99% | 1.72x |
|
IBRX
ImmunityBio, Inc.
|
245.4% | 1.110 | 42.14% | 4.62x |
|
INSM
Insmed, Inc.
|
50.57% | 1.883 | 2.03% | 3.35x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CMPX
Compass Therapeutics, Inc.
|
-$370K | -$18M | -42.75% | -45.22% | -1770% | -$13.3M |
|
EKSO
Ekso Bionics Holdings, Inc.
|
$1.7M | -$4.5M | -71.64% | -106.25% | -143.6% | -$4.5M |
|
FOLD
Amicus Therapeutics, Inc.
|
$156.8M | $15.9M | -4.09% | -12.36% | 8.61% | $16M |
|
IBRX
ImmunityBio, Inc.
|
$34M | -$64.7M | -117.98% | -- | -168.95% | -$71.7M |
|
INSM
Insmed, Inc.
|
$217.7M | -$249.7M | -77.98% | -192.35% | -94.64% | -$294.2M |
Compass Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns CMPX or EKSO?
Ekso Bionics Holdings, Inc. has a net margin of -1538.35% compared to Compass Therapeutics, Inc.'s net margin of -148.85%. Compass Therapeutics, Inc.'s return on equity of -45.22% beat Ekso Bionics Holdings, Inc.'s return on equity of -106.25%.
Company Gross Margin Earnings Per Share Invested Capital CMPXCompass Therapeutics, Inc.-- -$0.09 $206.6M EKSOEkso Bionics Holdings, Inc.53.22% -$1.57 $13.7M -
What do Analysts Say About CMPX or EKSO?
Compass Therapeutics, Inc. has a consensus price target of $13.64, signalling upside risk potential of 150.33%. On the other hand Ekso Bionics Holdings, Inc. has an analysts' consensus of $9.50 which suggests that it could grow by 1.06%. Given that Compass Therapeutics, Inc. has higher upside potential than Ekso Bionics Holdings, Inc., analysts believe Compass Therapeutics, Inc. is more attractive than Ekso Bionics Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CMPXCompass Therapeutics, Inc.13 0 0 EKSOEkso Bionics Holdings, Inc.1 1 0 -
Is CMPX or EKSO More Risky?
Compass Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ekso Bionics Holdings, Inc. has a beta of 0.775, suggesting its less volatile than the S&P 500 by 22.496%.
-
Which is a Better Dividend Stock CMPX or EKSO?
Compass Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ekso Bionics Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compass Therapeutics, Inc. pays -- of its earnings as a dividend. Ekso Bionics Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CMPX or EKSO?
Compass Therapeutics, Inc. quarterly revenues are --, which are smaller than Ekso Bionics Holdings, Inc. quarterly revenues of $3.1M. Compass Therapeutics, Inc.'s net income of -$15.7M is lower than Ekso Bionics Holdings, Inc.'s net income of -$4.7M. Notably, Compass Therapeutics, Inc.'s price-to-earnings ratio is -- while Ekso Bionics Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compass Therapeutics, Inc. is -- versus 5.32x for Ekso Bionics Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CMPXCompass Therapeutics, Inc.-- -- -- -$15.7M EKSOEkso Bionics Holdings, Inc.5.32x -- $3.1M -$4.7M
-
Which has Higher Returns CMPX or FOLD?
Amicus Therapeutics, Inc. has a net margin of -1538.35% compared to Compass Therapeutics, Inc.'s net margin of 0.91%. Compass Therapeutics, Inc.'s return on equity of -45.22% beat Amicus Therapeutics, Inc.'s return on equity of -12.36%.
Company Gross Margin Earnings Per Share Invested Capital CMPXCompass Therapeutics, Inc.-- -$0.09 $206.6M FOLDAmicus Therapeutics, Inc.84.64% $0.01 $716.6M -
What do Analysts Say About CMPX or FOLD?
Compass Therapeutics, Inc. has a consensus price target of $13.64, signalling upside risk potential of 150.33%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 0.42%. Given that Compass Therapeutics, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Compass Therapeutics, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CMPXCompass Therapeutics, Inc.13 0 0 FOLDAmicus Therapeutics, Inc.0 7 0 -
Is CMPX or FOLD More Risky?
Compass Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.483, suggesting its less volatile than the S&P 500 by 51.684%.
-
Which is a Better Dividend Stock CMPX or FOLD?
Compass Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compass Therapeutics, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CMPX or FOLD?
Compass Therapeutics, Inc. quarterly revenues are --, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $185.2M. Compass Therapeutics, Inc.'s net income of -$15.7M is lower than Amicus Therapeutics, Inc.'s net income of $1.7M. Notably, Compass Therapeutics, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compass Therapeutics, Inc. is -- versus 7.06x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CMPXCompass Therapeutics, Inc.-- -- -- -$15.7M FOLDAmicus Therapeutics, Inc.7.06x -- $185.2M $1.7M
-
Which has Higher Returns CMPX or IBRX?
ImmunityBio, Inc. has a net margin of -1538.35% compared to Compass Therapeutics, Inc.'s net margin of -161.83%. Compass Therapeutics, Inc.'s return on equity of -45.22% beat ImmunityBio, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CMPXCompass Therapeutics, Inc.-- -$0.09 $206.6M IBRXImmunityBio, Inc.88.91% -$0.06 $345.1M -
What do Analysts Say About CMPX or IBRX?
Compass Therapeutics, Inc. has a consensus price target of $13.64, signalling upside risk potential of 150.33%. On the other hand ImmunityBio, Inc. has an analysts' consensus of $14.80 which suggests that it could grow by 102.74%. Given that Compass Therapeutics, Inc. has higher upside potential than ImmunityBio, Inc., analysts believe Compass Therapeutics, Inc. is more attractive than ImmunityBio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CMPXCompass Therapeutics, Inc.13 0 0 IBRXImmunityBio, Inc.4 0 0 -
Is CMPX or IBRX More Risky?
Compass Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ImmunityBio, Inc. has a beta of 0.047, suggesting its less volatile than the S&P 500 by 95.312%.
-
Which is a Better Dividend Stock CMPX or IBRX?
Compass Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ImmunityBio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compass Therapeutics, Inc. pays -- of its earnings as a dividend. ImmunityBio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CMPX or IBRX?
Compass Therapeutics, Inc. quarterly revenues are --, which are smaller than ImmunityBio, Inc. quarterly revenues of $38.3M. Compass Therapeutics, Inc.'s net income of -$15.7M is higher than ImmunityBio, Inc.'s net income of -$62M. Notably, Compass Therapeutics, Inc.'s price-to-earnings ratio is -- while ImmunityBio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compass Therapeutics, Inc. is -- versus 60.49x for ImmunityBio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CMPXCompass Therapeutics, Inc.-- -- -- -$15.7M IBRXImmunityBio, Inc.60.49x -- $38.3M -$62M
-
Which has Higher Returns CMPX or INSM?
Insmed, Inc. has a net margin of -1538.35% compared to Compass Therapeutics, Inc.'s net margin of -124.5%. Compass Therapeutics, Inc.'s return on equity of -45.22% beat Insmed, Inc.'s return on equity of -192.35%.
Company Gross Margin Earnings Per Share Invested Capital CMPXCompass Therapeutics, Inc.-- -$0.09 $206.6M INSMInsmed, Inc.82.51% -$1.54 $1.5B -
What do Analysts Say About CMPX or INSM?
Compass Therapeutics, Inc. has a consensus price target of $13.64, signalling upside risk potential of 150.33%. On the other hand Insmed, Inc. has an analysts' consensus of $214.32 which suggests that it could grow by 31.94%. Given that Compass Therapeutics, Inc. has higher upside potential than Insmed, Inc., analysts believe Compass Therapeutics, Inc. is more attractive than Insmed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CMPXCompass Therapeutics, Inc.13 0 0 INSMInsmed, Inc.17 0 0 -
Is CMPX or INSM More Risky?
Compass Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.100, suggesting its more volatile than the S&P 500 by 10.036%.
-
Which is a Better Dividend Stock CMPX or INSM?
Compass Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compass Therapeutics, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CMPX or INSM?
Compass Therapeutics, Inc. quarterly revenues are --, which are smaller than Insmed, Inc. quarterly revenues of $263.8M. Compass Therapeutics, Inc.'s net income of -$15.7M is higher than Insmed, Inc.'s net income of -$328.5M. Notably, Compass Therapeutics, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compass Therapeutics, Inc. is -- versus 53.27x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CMPXCompass Therapeutics, Inc.-- -- -- -$15.7M INSMInsmed, Inc.53.27x -- $263.8M -$328.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 5
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 5
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 5
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
